BIO-key International (NASDAQ:BKYI – Get Free Report) announced its quarterly earnings results on Thursday. The technology company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.26, FiscalAI reports. The firm had revenue of $1.92 million during the quarter, compared to analyst estimates of $1.80 million. BIO-key International had a negative return on equity of 70.21% and a negative net margin of 60.59%.
BIO-key International Stock Performance
Shares of BIO-key International stock traded down $0.37 during trading hours on Friday, reaching $3.40. The company’s stock had a trading volume of 62,390 shares, compared to its average volume of 166,898. The company has a market capitalization of $3.71 million, a P/E ratio of -0.61 and a beta of 0.44. BIO-key International has a one year low of $2.96 and a one year high of $19.70. The stock’s fifty day simple moving average is $4.36 and its two-hundred day simple moving average is $5.25.
Wall Street Analyst Weigh In
BKYI has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BIO-key International in a research note on Friday, July 17th. Zacks Research upgraded BIO-key International to a “hold” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce”.
Institutional Investors Weigh In On BIO-key International
A hedge fund recently raised its position in BIO-key International stock. Geode Capital Management LLC lifted its position in BIO-key International Inc. (NASDAQ:BKYI – Free Report) by 49.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 48,892 shares of the technology company’s stock after acquiring an additional 16,271 shares during the quarter. Geode Capital Management LLC owned 0.45% of BIO-key International worth $26,000 at the end of the most recent reporting period. Institutional investors own 26.51% of the company’s stock.
About BIO-key International
BIO-key International, Inc is a developer and provider of fingerprint biometric identity and access management solutions, serving enterprise and government customers. The company’s core offerings include a range of fingerprint readers and authentication software designed to verify user identity across physical and digital environments. By leveraging proprietary template-on-card and template-on-device technologies, BIO-key seeks to enhance security and streamline user access without reliance on traditional passwords.
In addition to hardware sensors, BIO-key delivers software platforms that integrate with existing IT infrastructures such as Microsoft Active Directory and major workforce management systems.
Featured Stories
- Five stocks we like better than BIO-key International
- Sandisk’s Margins Look Like Software. Can They Last?
- CAVA Earnings: The Easiest Comp of the Year Meets a Tough Valuation
- Joint Operations: Curaleaf Makes a Play for Aurora Cannabis
- Cerebras Sells Off After Earnings: Is This a Market Disconnection?
Receive News & Ratings for BIO-key International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-key International and related companies with MarketBeat.com's FREE daily email newsletter.
